Antiangiogenesis in the treatment of NSCLC. Part 2 of a 3-part series

Targeting VEGF - Current and future research directions

Roy S. Herbst, Alan B. Sandler, David H. Johnson

Research output: Contribution to journalArticle

Abstract

There is a great need for new therapeutic approaches in non-small cell lung cancer (NSCLO), which is the leading cause of cancer deaths in the United States. Antiangiogenesis has come to the forefront to fill this need. Therapeutics that target various proangiogenic factors, such as vascular endothelial growth factor (VEGF), are thought to prevent tumor growth and future metastases by inhibiting tumor blood vessel formation. These agents are being tested alone, in combination with each other, and with chemotherapy. Initial results suggest that the biologics may work synergistically and may improve the ability of traditional chemotherapeutics to attack tumor cells. Three types of anti-angiogenic drugs are currently being tested for NSCLC: monoclonal antibodies, small molecule inhibitors that target single pathways, and multitargeted inhibitors. The most heavily investigated agent is bevacizumab, a monoclonal antibody against VEGF. Other the rapeutics include the epidermal growth factor receptor inhibitor erlotinib and the multitargeted agents ZD6474 and sorafenib. Future areas of research in NSCLC will include using the most effective therapies in less advanced disease settings, overcoming the resistance to certain biologics seen in some patient populations, and pinpointing the most appropriate settings and combinations in which to use the biologic agents.

Original languageEnglish (US)
JournalClinical Advances in Hematology and Oncology
Volume3
Issue number9 SUPPL. 10
StatePublished - Sep 2005

Fingerprint

Vascular Endothelial Growth Factor A
Biological Products
Monoclonal Antibodies
Vascular Tissue Neoplasms
Neoplasms
Angiogenesis Inhibitors
Biological Factors
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Cause of Death
Therapeutics
Neoplasm Metastasis
Drug Therapy
Growth
Research
Population
Direction compound
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
Erlotinib Hydrochloride
sorafenib

Keywords

  • Angiogenesis
  • Antiangenesis
  • Lung cancer
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{4c19f24c53a24bbbb99b8b60bb752578,
title = "Antiangiogenesis in the treatment of NSCLC. Part 2 of a 3-part series: Targeting VEGF - Current and future research directions",
abstract = "There is a great need for new therapeutic approaches in non-small cell lung cancer (NSCLO), which is the leading cause of cancer deaths in the United States. Antiangiogenesis has come to the forefront to fill this need. Therapeutics that target various proangiogenic factors, such as vascular endothelial growth factor (VEGF), are thought to prevent tumor growth and future metastases by inhibiting tumor blood vessel formation. These agents are being tested alone, in combination with each other, and with chemotherapy. Initial results suggest that the biologics may work synergistically and may improve the ability of traditional chemotherapeutics to attack tumor cells. Three types of anti-angiogenic drugs are currently being tested for NSCLC: monoclonal antibodies, small molecule inhibitors that target single pathways, and multitargeted inhibitors. The most heavily investigated agent is bevacizumab, a monoclonal antibody against VEGF. Other the rapeutics include the epidermal growth factor receptor inhibitor erlotinib and the multitargeted agents ZD6474 and sorafenib. Future areas of research in NSCLC will include using the most effective therapies in less advanced disease settings, overcoming the resistance to certain biologics seen in some patient populations, and pinpointing the most appropriate settings and combinations in which to use the biologic agents.",
keywords = "Angiogenesis, Antiangenesis, Lung cancer, Vascular endothelial growth factor receptor",
author = "Herbst, {Roy S.} and Sandler, {Alan B.} and Johnson, {David H.}",
year = "2005",
month = "9",
language = "English (US)",
volume = "3",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "9 SUPPL. 10",

}

TY - JOUR

T1 - Antiangiogenesis in the treatment of NSCLC. Part 2 of a 3-part series

T2 - Targeting VEGF - Current and future research directions

AU - Herbst, Roy S.

AU - Sandler, Alan B.

AU - Johnson, David H.

PY - 2005/9

Y1 - 2005/9

N2 - There is a great need for new therapeutic approaches in non-small cell lung cancer (NSCLO), which is the leading cause of cancer deaths in the United States. Antiangiogenesis has come to the forefront to fill this need. Therapeutics that target various proangiogenic factors, such as vascular endothelial growth factor (VEGF), are thought to prevent tumor growth and future metastases by inhibiting tumor blood vessel formation. These agents are being tested alone, in combination with each other, and with chemotherapy. Initial results suggest that the biologics may work synergistically and may improve the ability of traditional chemotherapeutics to attack tumor cells. Three types of anti-angiogenic drugs are currently being tested for NSCLC: monoclonal antibodies, small molecule inhibitors that target single pathways, and multitargeted inhibitors. The most heavily investigated agent is bevacizumab, a monoclonal antibody against VEGF. Other the rapeutics include the epidermal growth factor receptor inhibitor erlotinib and the multitargeted agents ZD6474 and sorafenib. Future areas of research in NSCLC will include using the most effective therapies in less advanced disease settings, overcoming the resistance to certain biologics seen in some patient populations, and pinpointing the most appropriate settings and combinations in which to use the biologic agents.

AB - There is a great need for new therapeutic approaches in non-small cell lung cancer (NSCLO), which is the leading cause of cancer deaths in the United States. Antiangiogenesis has come to the forefront to fill this need. Therapeutics that target various proangiogenic factors, such as vascular endothelial growth factor (VEGF), are thought to prevent tumor growth and future metastases by inhibiting tumor blood vessel formation. These agents are being tested alone, in combination with each other, and with chemotherapy. Initial results suggest that the biologics may work synergistically and may improve the ability of traditional chemotherapeutics to attack tumor cells. Three types of anti-angiogenic drugs are currently being tested for NSCLC: monoclonal antibodies, small molecule inhibitors that target single pathways, and multitargeted inhibitors. The most heavily investigated agent is bevacizumab, a monoclonal antibody against VEGF. Other the rapeutics include the epidermal growth factor receptor inhibitor erlotinib and the multitargeted agents ZD6474 and sorafenib. Future areas of research in NSCLC will include using the most effective therapies in less advanced disease settings, overcoming the resistance to certain biologics seen in some patient populations, and pinpointing the most appropriate settings and combinations in which to use the biologic agents.

KW - Angiogenesis

KW - Antiangenesis

KW - Lung cancer

KW - Vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=35848944878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848944878&partnerID=8YFLogxK

M3 - Article

VL - 3

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 9 SUPPL. 10

ER -